9月23日，深圳华大基因股份有限公司公告披露，控股股东深圳华大基因科技有限公司(华大控股)及其 一致行动人汪建、深圳华大三生园科技有限公司发生权益变动。汪建现任华大基因董事长、华大控股董 事长，其通过询价转让方式出让1673.27万股股份，占公司总股本的4.00%，成交价格为44.10元/股，交 易金额约7.38亿元。事实上，这已是华大控股今年的第二次大额减持。两次合计，汪建及华大控股在 2025年已减持套现金额超过11亿元。 由于华大控股为汪建全资控制企业，这意味着，其实际套现超过7亿元。本次交易共有29家基金公司接 盘，其中包括易方达、财通、华夏、诺德、国泰等头部机构。 事实上，这已是华大控股今年的第二次大额减持。3月11日至14日，公司曾通过大宗交易累计减持 748.83万股，套现约4.2亿元。 两次合计，汪建及华大控股在2025年已减持套现金额超过11亿元。 市场普遍认为，尽管机构积极参与，但创始人及控股股东的集中减持仍释放出资金压力与战略收缩的信 号。 现状 华大基因上半年营收降近13% 华大控股今年二次大额减持 交易完成后，华大控股持股比例降至29.77%，汪建直接持股0.61%，三生园科技持股0 ...

Group 1 - The core business of the company is to provide research services and comprehensive solutions for precision medicine testing through multi-omics big data technologies such as genetic testing, mass spectrometry, and bioinformatics analysis [1] - The company currently has no plans for additional issuance or placement of shares for financing [1]

Group 1 - The core business of the company includes gene testing, mass spectrometry testing, bioinformatics analysis, and medical AI models, providing comprehensive solutions for research services, precision medical testing, and health management [2] - The company has received multiple awards, including the "2023 Chinese Preventive Medicine Association Science and Technology Award" and recognition in the ESG field for its management practices [2] - The latest financial report shows a revenue of 672 million yuan for Q1 2025, a year-on-year decrease of 18.18%, and a net loss of approximately 52.7 million yuan, with a gross profit margin of 43.55% [3] Group 2 - As of May 29, the company's stock closed at 52.26 yuan, up 3.83%, with a latest price-to-book ratio of 2.39 and a total market capitalization of 21.731 billion yuan [1] - On May 29, the company experienced a net inflow of main funds amounting to 13.51 million yuan, with a total inflow of 57.99 million yuan over the past five days [1] - The company's price-to-earnings ratio (TTM) is -22.45, indicating a negative earnings performance compared to the industry average of 49.64 [3]

Core Insights - The company, BGI Genomics, reported a significant decline in its financial performance for 2024, with a net profit loss of 903 million yuan, marking its first annual net loss since its listing and the largest loss to date [1][2] Financial Performance - BGI Genomics achieved a revenue of 3.867 billion yuan in 2024, a year-on-year decrease of 11.10% [1] - The net profit attributable to shareholders was a loss of 903 million yuan, representing a staggering year-on-year decline of 1071.68% [1][2] - The company's net profit had peaked at 2.09 billion yuan in 2020, but has been on a downward trend since, with profits of 1.462 billion yuan in 2021, 803 million yuan in 2022, and 93 million yuan in 2023 [2] - Total assets decreased to 12.542 billion yuan, down 7.87% year-on-year, while net assets attributable to shareholders fell to 9.135 billion yuan, a reduction of 7.35% [2] Business Segment Performance - The infection prevention business saw a dramatic revenue drop of 85.91%, with earnings of only 73 million yuan in 2024 compared to 516 million yuan in 2023 [3] - Despite the downturn in the infection prevention segment, the reproductive health and oncology businesses maintained growth, with the precision medicine testing solutions segment showing a 22.37% increase when excluding the impact of public health events [3] Industry Outlook - The global genetic testing market is projected to grow from 19.66 billion USD in 2024 to 32.83 billion USD by 2029, with a compound annual growth rate of 10.81% [4] - The company plans to increase investments in medical AI models, intelligent testing platforms, and integrated multi-omics technologies to enhance its core competitiveness and adapt to market changes [4]